Soliton, Inc., (SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that the company has identified a third site as well as the supervising physician for its upcoming expanded pivotal Cellulite Trial.  The site joins two previously identified sites in what is anticipated to be a four-site trial.

Join our more than 200K fans here to follow the Company: https://soly-investors.com

The expanded Cellulite Clinical Trial builds upon a proof-of-concept trial conducted earlier this year.  Subjects will be treated at Chicago Cosmetic Surgery and Dermatology with treatment supervised by Omer Ibrahim, MD FAAD and Carolyn I. Jacob, MD FAAD, both Board Certified Dermatologists.  The data from the patients treated in Chicago will be added to the data from patients treated at Capital Laser in Chevy Chase, MD and at SkinCare Physicians in Boston.

Dr. Chris Capelli, President, CEO and co-founder of Soliton, commented, “This pivotal cellulite trial will ultimately take place in 4 sites located in major cities across the country, and will enroll up to 75 patients.  The study is designed to support our submission to the U.S. Food and Drug Administration.”

Cellulite affects up to 90% of women and over a billion dollars per year is spent on treatment in the U.S.  Results from our initial proof of concept clinical trial suggest the potential for a new approach to treating cellulite.  In the proof of concept trial, the Soliton Rapid Acoustic Pulse (“RAP”) device was applied to the surface of the patients’ skin for a single 20-minute, non-invasive treatment.  The treatments required no anesthesia, caused no bruising, swelling or infection, and were evaluated by the trial participants as a “0” on a pain scale of 0-10 in 97% of the treatments.  None of the patients experienced any post-treatment downtime.  The Soliton device used in this trial has not been reviewed or cleared by the FDA for marketing and, accordingly, none of the information in this press release is intended to promote the sale or use of the device.  The device is investigational and is not available for sale in the United States.

About Soliton, Inc.

Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson.  The Company’s first FDA cleared commercial product will use rapid pulses of acoustic shockwaves as an accessory to lasers for the removal of unwanted tattoos.  The Company is based in Houston, Texas, and is actively engaged in bringing the Rapid Acoustic Pulse (“RAP”) device to the market.  The Company believes this “Soliton” method has the potential to lower tattoo removal costs for patients, while increasing profitability to practitioners, compared to current laser removal methods.  Soliton is investigating potential additional capabilities of the RAP technology in preclinical testing, including the potential to assist existing fat reduction technology in the reduction of fat as well as improving the appearance of cellulite by creating mechanical stress at the cellular level and inducing significant collagen growth.

For more information about the Company, please visit: http://www.soliton.com